2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1577

Periodontal Evaluation Is Associated with Increased Likelihood of Achieving Low Disease Activity in Rheumatoid Arthritis with Methotrexate
Abstract Number: 323

Perioperative Interventions for Smoking Cessation in Hip and Knee Arthroplasty for Osteoarthritis and Other Non-Traumatic Diseases
Abstract Number: 1922

Peripheral B Lymphocytes Secrete Both Interleukin 6 and Transforming Growth Factor-Beta and Potentiate Fibroblast Activation in Systemic Sclerosis
Abstract Number: 820

Peripheral Blood and Disease Features Associated with Complement Components C3 and C4 in SLE
Abstract Number: 1430

Peripheral HMGB1 Regulates Arthrtis-Associated Pain-like Behaviour
Abstract Number: 2268

Peripheral Joint MRI for Inflammatory Arthritis and the Choosing Wisely Campaign – Evidence for Wide Variations in Use
Abstract Number: 3170

Peripheral Osteoblastogenesis in Rheumatoid Arthritis Is Enhanced after TNF Blocker Treatment, Irrespective of Systemic Inflammation
Abstract Number: 486

Persistence Among Rheumatoid Arthritis Patients Initiating Intravenous or Subcutaneous Anti-Tumor Necrosis Factor Therapy in a Large US Registry Cohort
Abstract Number: 445

Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort
Abstract Number: 1282

Persistence with Osteoporosis Therapies in Postmenopausal Women in a Large US National Health Plan
Abstract Number: 2669

Persistency of Patient Reported Morning (AM) Stiffness in a Large US Registry Cohort of Rheumatoid Arthritis (RA) Patients Initiating New DMARD Therapy
Abstract Number: 2731

Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry
Abstract Number: 2928

Persistent Disease Activity over Time in a Large Canadian Cohort of Prevalent Lupus Patients
Abstract Number: 1286

Persistent Individual and Neighborhood Poverty Are Independent Risk Factors for Accumulated Lupus Damage
Abstract Number: 1495

Person-Centred Care Can Help Patients to Become More Effective Consumers in the Use of Health Information Than Regular Care – an RCT in Patients with Arthritis Undergoing Biological Therapy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].